Reza Pari-Nejad

📣 | Newcells Biotech launches high-content and high-throughput imaging suite to advance pre-clinical drug development programmes. We are delighted to announce the launch of our new imaging suite and advanced lung Fibroblast-to-Myofibroblast Transition (FMT) assay. Comprising high-content and high-throughput equipment, the state-of-the-art imaging suite will provide more in-depth and robust in vitro data. The advanced high-throughput high-sensitivity lung FMT assay facilitates customisable and rapid assessment of the efficacy of anti-fibrotic drug candidates. 💬 “The launch of our new imaging suite and enhanced fibrotic disease screening assay is a key step in our strategy to provide innovative, market-leading in vitro models that advance the discovery and safe development of new drugs." - Dr Mike Nicholds, CEO and Co-Founder, Newcells Biotech Read the full press release to learn more: https://lnkd.in/gNBAEP3e #Newcells #DrugDevelopment #FMT #InVitroData #HighContentImaging

43

8 Comments

https://lnkd.in/eWsz7CcU With over 60 references, The Neospora Antibody Test Kit from VMRD, Inc. and available from 2BScientific Ltd. employs a competitive ELISA technique to detect the presence of Neospora caninum antibodies in serum samples from cattle. 🐝 Exceptional Precision: Evidenced through sensitivity and specificity assessments, ensuring dependable identification of both positive and negative sera. 🐝 Distinct Discrimination: 5% of sera registered within ±5% of the cut-off value, underscoring exact differentiation between positive and negative samples. 🐝 Streamlined Screening: Streamlines the examination of extensive sample sets, as evidenced by the analysis of 4,323 sera with unknown serologic statuses. 🐝 Robust Confidence: Minimal overlap near the cut-off value inspires assurance in the kit's accuracy. For your own research reagents, get in contact at [email protected] with any queries about this ELISA, our products, or anything concerning life science! #petwelfare #neospora #hereforyou

4

Want to catch bacterial contamination early in your CHO cell cultures? Aber Instruments Ltd's webinar (link below!) explores how conductivity & dielectric spectroscopy can help with real-time monitoring & process automation. https://lnkd.in/eQPxdiGj #WebinarAlert #bioprocess #biotechnology #ProcessAutomation #CellCulture #ContaminationDetection #learning

4

💵 Funding News: 🗓️ News Month: October, 2024 Antiverse Raises £3.5M Seed Funding to Revolutionize Antibody Design! 🧬 Cardiff-based Antiverse has closed a £3.5M Seed round to scale its mission of designing antibodies for challenging targets in healthcare! This funding, led by i&i Biotech Fund I and Kadmos Capital Ltd with additional participation from existing investors Innospark Ventures, UKI2S (managed by Future Planet Capital), Tensor Ventures, and AngelHub, brings Antiverse’s total funding to £7.2M. What’s Next for Antiverse: 🔹Team Expansion 🧑‍🔬: Strengthening the team with key new appointments. 🔸Advancing Antibody Design Programs 🔬: Pioneering partnerships with pharmaceutical companies to tackle tough targets like GPCRs and ion channels. How Antiverse Stands Out: 🔸Machine-Learning Approach 🤖: Leveraging structural and sequence data to create target-specific libraries with high predictive accuracy. 🔹Faster Discovery ⏱️: Reducing the antibody discovery process to just 6 months—a significant leap from traditional methods! With new facilities in Boston and Prague, Antiverse is on a global path to transform antibody discovery and bring vital therapies to patients faster. 📢 Stay tuned to Future Techly for the latest updates on this groundbreaking initiative and the latest in tech and business! 💥 Source: FinSMEs ♻️ Repost if you think this insight is worth sharing!

20

We are proud to introduce the Octet – Biolayer Interferometry (BLI) technology to our fleet! Experience unmatched speed and precision in your assays with BLI. Say goodbye to lengthy experiments and hello to real-time insights that help you make informed decisions faster than ever. 🔬 Don’t let slow assays hold you back—let’s collaborate! To Read More - www.genextgenomics.com #GeNextGenomics #OctetBLI #BiolayerInterferometry #RealTimeInsights #PrecisionAssays #FastAssays #InnovativeTechnology #BiotechAdvancements

34

1 Comment

European Heart Journal, Oct 2024 Olink Proteomics analysis identifies novel causal #biomarkers for Large #artery stiffness (LAS), a condition which significantly contributes to the burden of #cardiovascular #morbidity and #mortality. The identification of NPPB as a key biomarker could have important implications given the current availability of #FDA-approved medications to boost #NPPB effects. Therapeutically targeting LAS may help in mitigating cardiovascular disease and other #comorbidities. Title: "Proteome-wide associations of pulse pressure in the UK Biobank" Large artery stiffness (LAS) significantly contributes to the burden of cardiovascular morbidity and mortality, and is marked by an increased pulse pressure (PP). • Baseline #circulating protein levels for 2,941 protein analytes were measured using #Olink technology. • 61 out of 2,923 proteins were significantly associated with PP. • Genetically-predicted levels for 58 proteins were significantly associated with PP after FDR correction. • 31 proteins were concordantly associated with PP in both analyses, and 19 had consistent directions of effect, including natriuretic peptide B (NPPB), thrombospondin-2 (THBS2), paraoxonase-2 (PON2), and sclerostin (SOST). The findings will lead to further investigations regarding the #biology and #clinical role of the identified candidate #therapeutic targets. #Cardiology #heart #immunology #pathology #proteomics #omics #genomics #pharma https://lnkd.in/ggr_Ztad

10

1 Comment

Happy to announce LGC Biosearch Technologies has developed a proprietary client facing software for SNP calling available to end users purchasing AMP-Seq genotyping products as requested by our clients (https://lnkd.in/eEajGin4). Known as BiosearchCaller, the caller itself allows multiple models for SNP calling including de novo discovery of SNPs within amplicons and short indels. While we typically offer VCF file generation through our own pipeline, this will allow end users greater flexibility in choosing the model best suited for their organism. Works on both diploids and polyploids. See below for existing panels if you want to try it in your lab (parentage, genomic selection): #NGS #Genomics #SNP #GWAS #GEBV #GenomicSelection #Agriculture #Maize #HighThroughput #Genotype #Soy #Bovine #Pig #Canola #Sorghum #Strawberry #Wheat #Parentage

14

'Isn't everyone moving to single cell suspension culture?' A question posed to me last week during an enjoyable investor conversation. It's not the first time we have heard this, nor will it be the last. mABs production set a precedent for single-cell suspension culture, AAV is following in it's footsteps (mostly). It's 100% the right route forward for certain products, however, not all. Adherent cell culture isn't the 'sexy' part of the industry. For decades, it has been difficult and costly to scale. It's still shockingly inefficient which for CellRev equals big opportunity. The microcarrier market is growing very healthily. So, whether it's sexy or not, it's a beautiful not-so-little niche. Our friends Sartorius Stedim Biotech, Cytiva, and Corning LifeScience have thus far dominated the space. However, the entry of new solutions from the likes of Kuraray and Carroucell further demonstrates growing interest in the market. #bioprocessing #cellculture #celltherapies #beautifulculture ________________ CellRev provide media additives to transform process yield with a focus on upstream sticky cell problems such as aggregation, clumping, and cell detachment. Our solutions prevent or reduce cell death. Live Cells. Lives Saved. Credit Emergen Research

22

4 Comments

Congratulations to the Nanocomp team for Commercial Activity of the Year award received at the SSPC, SFI Research Centre for Pharmaceuticals Annual Symposium this week at the University of Limerick. Working with Sarah Hudson on stage 1 of this project was arduous and a drag…as you can see from our faces in the picture below 😃. I mean, you can’t fake that kind of “chemistry”! I loved working with Nanocomp team every day even though they spoke a foreign language to me. I had to learn a whole new field of science from scratch. In every step they patiently taught me the basics, answered my silly questions, and through it all these highly respected and established scientists were always curious and open about what I had to say from the commercial perspective. That is why after a year’s hiatus, I decided to join them again. When I was considering all the opportunities that came my way in the last few months, I prioritized team dynamic and intellectual challange over other factors. Let’s face it, life is not getting any longer. It’s good to know what you need to get you out of bed every day. (Plus I get to say “plasma” in serious sentences a couple of times a week and for a Trekkie that’s reason enough no?!) Nanocomp is a novel solid drug formulation technology that can potentially enable more therapies to reach the market with significant manufacturing efficiencies and a smaller gentler environmental footprint. Considering the number of therapeutic molecules in the pipeline that are poorly water soluble, this is a very worthwhile venture to explore. I’ll spend the next year finalizing the business plan. Congratulations to the Nanocomp team on this award that is a testament to your dedication and hard work on this project: professors kieran hodnett Peter Davern Åke Rasmuson and the young scientists who built up an impressive body of data to support our claims: Ajay Kumar, Promita Bhattacharjee, Marta Bergillos Ruiz and Peuli Ghosh. Many thanks for SSPC, SFI Research Centre for Pharmaceuticals for the award and for investing so much in the supportive environment that allows innovation to thrive. And of course many thanks to Enterprise Ireland for generously funding this project and enabling the Nanocomp team to come together and do more. Majella Maher our EI advisor and partner in crime, thank you for keeping us on the righteous path and enabling this project every step of the way. You should be in this picture. We will miss you dearly as we finish stage 2. #Chemistry! Here we go again (literally and figuratively). And Bravo Nanocomp. #SSPC15 #UL

150

7 Comments

Our Charnwood Discovery biology team have utilised a number of autophagy assays based on autophagy regulator LC3B to facilitate drug discovery projects across various therapeutic areas. This has included Promega Corporation NanoBiT autophagy reporter cell lines, Revvity AlphaLISA, Thermo Fisher Scientific Cellinsight CX5 High Content Imaging (see figure below) and Bio-Techne WES-based Western Blotting. Furthermore a HTS (384-well format) using the HEK-293 NanoBiT assay was used to screen for both autophagy enhancers and inhibitors. Read about our work, results and conclusions here 👉https://lnkd.in/es5JvGtZ #discoverybiology #autophagy #cellbiology #drugdiscovery

18

Antibody purification is an essential step in producing high-quality antibodies, but there's no one 'right' approach. At evitria, we offer a range of purification services designed to meet the diverse needs of our clients' projects. This includes offering alternative resins to aid protein capture for antibodies without a strong affinity to Protein A. Find out what these are and the methods we use for protein polishing in our blog. If you have any questions, please message me or the rest of the team. With evitria, your project is in safe hands. #AntibodyManufacturing #Antibodies #AntibodyPurification #ProteinCapture

14

🌍 What pushes scientists to become entrepreneurs?     On World Entrepreneurs’ Day, find out how Ishani Malhotra built Carcinotech Ltd’s 3D bioprinting platform to accelerate drug discovery and development.    Read more 👉 https://lnkd.in/ewcsZDis    #OnMyHorizon #WomeninSTEM #WorldEntrepreneursDay 

104

5 Comments

🚀 Revolutionising Proteomics with Evotip Pure! 🚀 In the ever-evolving field of proteomics, achieving high sensitivity and reproducibility with minimal sample loss is paramount. Enter Evotip Pure, a groundbreaking solution that seamlessly integrates with LC-MS workflows to enhance your research capabilities! 🔬 Key Highlights of Evotip Pure 🔬 Efficient Sample Recovery: Designed to concentrate low-input samples while reducing handling steps, Evotip Pure ensures maximum recovery and minimal loss to plasticware. This is critical for single-cell proteomics, where every cell counts. Robust & Scalable Workflows: Evotip Pure supports high-sensitivity analyses and offers scalable solutions for both small and large sample volumes. It’s a perfect fit for advanced proteomics workflows that demand precision and consistency. Minimized Carryover: With its innovative design, Evotip Pure minimizes carryover and simplifies storage complexities, ensuring clean and reliable data across sequential runs. This means more accurate results and less downtime. Enhanced Reproducibility: The technology’s partial elution capability protects your samples and the analytical system, promoting consistent results across multiple analyses. Evotip Pure's robustness is demonstrated across hundreds of samples with stable pressure and retention times. Versatile & Precise: Whether you're handling high-load plasma or single-cell equivalents, Evotip Pure delivers quantitative precision with low median CVs, making it ideal for diverse proteomic applications. Future-Ready Integration: Evotip Pure integrates seamlessly with automated workflows, paving the way for high-throughput and scalable single-cell proteomics. This forward-thinking approach supports the next generation of scientific discovery. 🔗 Unlock the full potential of your proteomics research with Evotip Pure and elevate your lab’s capabilities to new heights! #Proteomics #SingleCell #LCMS #ResearchInnovation #EvotipPure #ScientificDiscovery #LabTechnology

5

Macrocycles are becoming increasingly popular in drug discovery, due to their vast potential against previously "undruggable" targets. But the size and complexity of these molecules means that their design and optimisation is far from easy.  Join Drs Ajay Jain and Ann Cleves Jain as they explore how to accurately predict the conformations and properties of macrocycles. They’ll be discussing: 🌟How to effectively model structurally complex macrocycles for lead optimisation 🌟How to apply biophysical constraints to help model very large peptidic macrocycles 🌟Different modelling methods using protein structure, and using purely ligand-based machine learning approaches 🌟Two practical case studies of effective macrocyclic lead optimisation using the BioPharmics platform Following the presentation there will be an interactive Q&A session, to answer all your burning questions on the topic. Register now at https://lnkd.in/eUZVQUcq #Macrocycles #DrugOptimisation #ComputationalChemistry #Pharma

27

Developing a Target Product Profile (TPP) very early on in ATMP development is crucial to ensure that your therapeutic product is designed to meet its intended use and regulatory requirements, increasing the likelihood of producing a safe, effective, and marketable product. Look at your TPP as a strategic document that serves as a common vision across various stakeholders, including regulatory agencies, investors, development and clinical teams, healthcare providers, and so on. It ensures that everyone has a clear understanding of the product’s goals and requirements, allowing for efforts and resources to be focused where needed.

24

In case you missed it last week, our webinar by Jonathan Frampton is now available to view here: https://lnkd.in/e_7Hz9TQ Listen to our insightful webinar where we delve into the challenges facing viral vector manufacturing in CGT. - Understand viral vector challenges - Discover innovative manufacturing solutions - Enhance capacity with advanced technologies

5

As data technologies continue to develop at pace, the question on the lips of many developers of diagnostics and other preventative interventions against AMR is how best to harness data technologies to make their products as efficient, cost-effective and accessible as possible. Managing data, sharing data and ensuring data privacy are also integral considerations. Here are some links with thoughts about what has been done before with regard to using data technologies for AMR diagnostic and prevention purposes and sharing of non-human microbial data https://bit.ly/3y6YaaU. #AMR #diagnostics #datatech #digitaltech #diagnosticdevelopment #AMRprevention

3

Interesting post here from Vincent Ling on one of the lesser talked about ripple effects of the current life sciences funding landscape. While 2024 has had its share of difficulties, there's still a silver lining for CROs. Rising costs are making in-house drug development increasingly unsustainable. This reality is fueling the growth of the CRO sector. In fact, according to Fortune Business Insights, the CRO market is projected to expand from $86.33 billion in 2024 to $175.46 billion by 2032. That’s a compounded annual growth rate of 9.3%. And the good news doesn’t stop there.  WCG reports that the demand for new clinical trials is now surpassing the number of available research sites.  This mismatch is creating opportunities for CROs to step in and bridge the gap. Add to that the accelerating integration of artificial intelligence and machine learning, and the future of the CRO industry looks even brighter. It’s clear: despite the hurdles, a resurgence is on the horizon for CROs.

9

1 Comment